Filtered By:
Condition: Hypertension
Countries: Canada Health
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 229 results found since Jan 2013.
Hypertension Canada ’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
Publication date: Available online 1 March 2018 Source:Canadian Journal of Cardiology Author(s): Kara A. Nerenberg, Kelly B. Zarnke, Alexander A. Leung, Kaberi Dasgupta, Sonia Butalia, Kerry McBrien, Kevin C. Harris, Meranda Nakhla, Lyne Cloutier, Mark Gelfer, Maxime Lamarre-Cliche, Alain Milot, Peter Bolli, Guy Tremblay, Donna McLean, Raj S. Padwal, Karen C. Tran, Steven Grover, Simon W. Rabkin, Gordon W. Moe, Jonathan G. Howlett, Patrice Lindsay, Michael D. Hill, Mike Sharma, Thalia Field, Theodore H. Wein, Ashkan Shoamanesh, George K. Dresser, Pavel Hamet, Robert J. Herman, Ellen Burgess, Steven E. Gryn, Jean C. Grégo...
Source: Canadian Journal of Cardiology - March 2, 2018 Category: Cardiology Source Type: research
The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus
Publication date: April 2018 Source:Canadian Journal of Diabetes, Volume 42, Issue 2 Author(s): Martin H. Strauss, Alistair S. Hall The renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's also red...
Source: Canadian Journal of Diabetes - March 28, 2018 Category: Endocrinology Source Type: research
Invasive Hemodynamics and Rejection Rates in Patients with Cardiac Sarcoidosis After Heart Transplantation
Conclusions CS patients have similar post-transplant hemodynamics as non-CS patients, without evidence of RV dysfunction or pulmonary hypertension. No significant rejection nor recurrence of sarcoid in the allograft were observed in this cohort of patients with CS. Survival is similar between CS and non-CS patients. Heart transplant is a viable strategy in selected CS patients with excellent outcomes. Teaser Orthotopic heart transplant (OHT) is utilized for end-stage heart failure due to cardiac sarcoidosis (CS). There is a lack of data on long-term outcomes. We explored changes in hemodynamics, allograft rejection and sur...
Source: Canadian Journal of Cardiology - April 7, 2018 Category: Cardiology Source Type: research
Blood Pressure –Lowering Targets in Patients With Diabetes Mellitus
Publication date: May 2018 Source:Canadian Journal of Cardiology, Volume 34, Issue 5 Author(s): Alexander A. Leung, Raj S. Padwal Diabetes is a highly prevalent medical condition that commonly coexists with hypertension. The presence of diabetes and hypertension significantly increases the risk of adverse cardiovascular events. Although compelling evidence exists from randomized controlled trials demonstrating that blood pressure (BP) reduction effectively prevents cardiovascular complications, optimal BP targets remain uncertain and continue to be the subject of ongoing controversy. Until recently, most major clinical pr...
Source: Canadian Journal of Cardiology - May 4, 2018 Category: Cardiology Source Type: research
Applicability of the Systolic Blood Pressure Intervention Trial (SPRINT) to the Canadian Population
Conclusions If fully implemented, intensive systolic BP lowering to < 120 mm Hg in SPRINT-eligible high-risk individuals would substantially increase the proportion of Canadian adults receiving BP treatment initiation or intensification.
Source: Canadian Journal of Cardiology - May 4, 2018 Category: Cardiology Source Type: research
Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study
by Amol A. Verma, Wayne Khuu, Mina Tadrous, Tara Gomes, Muhammad M. Mamdani
BackgroundThe majority of people with hypertension require more than one medication to achieve blood pressure control. Many patients are prescribed multipill antihypertensive regimens rather than single-pill fixed-dose combination (FDC) treatment. Although FDC use may improve medication adherence, the impact on patient outcomes is unclear. We compared clinical outcomes and medication adherence with FDC therapy versus multipill combination therapy in a real-world setting using linked clinical and administrative databases. Methods and findingsWe cond...
Source: PLoS Medicine - June 11, 2018 Category: Internal Medicine Authors: Amol A. Verma Source Type: research
Effects of Riociguat on Right Ventricular Remodeling in Chronic Thromboembolic Pulmonary Hypertension Patients: A Prospective Study
Conclusions Riociguat treatment was associated with increased RVSVI and trends for improvement in myocardial remodeling in CTEPH patients. A larger clinical study is warranted to observe the therapeutic benefits of riociguat on RV remodeling. Teaser Riociguat is an approved medical treatment for chronic thromboembolic pulmonary hypertension (CTEPH) patients. We studied the effects of riociguat treatment on right ventricular (RV) remodeling by means of magnetic resonance imaging (MRI) and positron emission tomography (PET). After 6 months of riociguat treatment in 6 CTEPH patients, RV function increased, fibrosis decreased ...
Source: Canadian Journal of Cardiology - June 26, 2018 Category: Cardiology Source Type: research
Vascular Plugging for the Enlarging Pulmonary Arteriovenous Malformation in a Patient With Idiopathic Pulmonary Artery Hypertension
We report on a lady with PAVM and idiopathic pulmonary artery hypertension who, within 2 years of diagnosis, had an ischemic stroke, PAVM enlargement from 20 × 20 × 30 mm to 30x × 40 × 40 mm and oximetry decrease to 90%. Transcatheter occlusion of PAVM with a vascular plug was successful. A year later, she had no flow via the PAVM and systemic oximetry improved to 97%, but pulmonary vascular resistance increased to 1.5-fold of baseline.RésuméLa coexistence de l’hypertension artérielle pulmonaire idiopathique et d’une malformation artérioveineuse pulmonaire (MAVP) s’avère problématique, car même si la M...
Source: Canadian Journal of Cardiology - July 5, 2018 Category: Cardiology Source Type: research
The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus
Publication date: April 2018Source: Canadian Journal of Diabetes, Volume 42, Issue 2Author(s): Martin H. Strauss, Alistair S. HallAbstractThe renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's als...
Source: Canadian Journal of Diabetes - July 5, 2018 Category: Endocrinology Source Type: research
Effects of Riociguat on Right Ventricular Remodeling in Chronic Thromboembolic Pulmonary Hypertension Patients: A Prospective Study
ConclusionsRiociguat treatment was associated with increased RVSVI and trends for improvement in myocardial remodeling in CTEPH patients. A larger clinical study is warranted to observe the therapeutic benefits of riociguat on RV remodeling.
Source: Canadian Journal of Cardiology - July 10, 2018 Category: Cardiology Source Type: research
Vascular Plugging for the Enlarging Pulmonary Arteriovenous Malformation in a Patient With Idiopathic Pulmonary Artery Hypertension
We report on a lady with PAVM and idiopathic pulmonary artery hypertension who, within 2 years of diagnosis, had an ischemic stroke, PAVM enlargement from 20 × 20 × 30 mm to 30x × 40 × 40 mm and oximetry decrease to 90%. Transcatheter occlusion of PAVM with a vascular plug was successful. A year later, she had no flow via the PAVM and systemic oximetry improved to 97%, but pulmonary vascular resistance increased to 1.5-fold of baseline.RésuméLa coexistence de l’hypertension artérielle pulmonaire idiopathique et d’une malformation artérioveineuse pulmonaire (MAVP) s’avère problématique, car même si la M...
Source: Canadian Journal of Cardiology - July 10, 2018 Category: Cardiology Source Type: research
The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus
Publication date: April 2018Source: Canadian Journal of Diabetes, Volume 42, Issue 2Author(s): Martin H. Strauss, Alistair S. HallAbstractThe renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's als...
Source: Canadian Journal of Diabetes - July 10, 2018 Category: Endocrinology Source Type: research
Another Chance for Medtronic ’s Renal Denervation Therapy
Medtronic has yet another chance to prove its renal denervation therapy can treat uncontrolled hypertension. The Dublin-based company has received FDA approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system with patients on medication for high blood pressure.
The ON MED Trial is a 2:1 randomized, sham-controlled study and will randomize up to 340 patients at 55 centers in the U.S., Japan, Europe, Australia and Canada. Patients will be followed out to three years. Primary safety endpoints will include major adverse events at one month and new renal artery stenosis at six months. The pri...
Source: MDDI - November 8, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
Descriptive analysis of pharmacy services provided after community pharmacy screening
Conclusions Approximately one-third of participants received a pharmacy service within 3 months post-screening. Relatively large numbers of annual and follow-up medication reviews were delivered despite low eligibility for annual-only reviews and despite many missed opportunities for pharmacy service provision in at-risk patients. In-pharmacy screening may facilitate provision of some services, namely medication reviews, by providing opportunities to identify patients at-risk.
Source: International Journal of Clinical Pharmacy - November 26, 2018 Category: Drugs & Pharmacology Source Type: research
